Advanced Filters
noise

Paris Cedex 20, France Clinical Trials

A listing of Paris Cedex 20, France clinical trials actively recruiting patients volunteers.

Found 2,271 clinical trials
r richard delorme, MD., PhD.

Phenotypic Exploration of Autism Spectrum Disorders Retrospective and Prospective Data

Autism Spectrum Disorders (ASD) are a heterogeneous group of severe developmental abnormalities of the nervous system characterized by deficits in social interaction and verbal and nonverbal communication affecting approximately 1% of the general population. In 5-40% of cases, genetic factors are identified as the cause of these disorders. Despite this …

1 - 18 years of age All Phase N/A
A ARNAULT Gwénaëlle, MD

Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS

Disorders of glycemic regulation are common in patients hospitalized for acute coronary syndrome (ACS). Abnormal glycaemia is observed in 50% of cases, in 30-40% diabetes, and in 25-35% fasting hyperglycaemia or glucose intolerance. Hyperglycemia is a major prognostic factor in ACS, with admission hyperglycemia having independent prognostic value for both …

18 - 85 years of age All Phase N/A
S Sandra VUKUSIC, MD

French Registry for Monitoring Pregnancies for Multiple Sclerosis

The influence of pregnancy on the course of multiple sclerosis (MS) has long been a controversial topic. After the publication of the first large prospective study of pregnancy and MS in 1998, counselling of women with MS has radically changed and many patients have been able to fulfill their desire …

years of age All Phase N/A
L Leila Mirtagui

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

12 - 85 years of age All Phase 1

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug …

25 - 60 years of age All Phase 1/2

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.

- 15 years of age All Phase N/A
F Frédéric SACHER, MD

Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Observatory for PAtients With Laminopathies and Emerinopathies)

Laminopathies and emerinopathies are complex group of rare disorders due to mutations in A-type lamins (LMNA) and Emerin (EMD) genes. Among them, disorders affecting skeletal and/or cardiac muscles are the most frequent clinical manifestations, with cardiac disease being a major cause of death. Remarkable progress has been made in the …

years of age All Phase N/A
M Margaret Von Mehren

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.

18 years of age All Phase 1

Registry of Coronary Artery Ill Patients With Platelet Test Results

ONASSIST is a registry of coronary ill patients who have had a functional test measuring anti-platelet effect and/or a genetic profile of response to anti-platelet drugs.

18 years of age All Phase N/A

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.

18 years of age All Phase 1/2

Simplify language using AI